FDA Turns Down MS Drug Lemtrada MedPage Today He indicated that biologic agents targeting specific immune cell classes -- the anti-CD25 drug daclizumab (Zenepax) and the B-cell depleting agent ocrelizumab -- also were promising for MS. Alemtuzumab had previously been sold under the name Campath ... |
